Dolutegravir + Lamivudine + Tenofovir Disoproxil Fumarate Tablets Manufacturer

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP manufactures Dolutegravir + Lamivudine + Tenofovir Disoproxil Fumarate Tablets for combination antiretroviral therapy in HIV infection treatment programs. The formulation is widely incorporated into long-term antiviral regimens aimed at suppressing viral replication and maintaining immune system stability.

Dolutegravir acts as an integrase strand transfer inhibitor preventing HIV genetic integration, while Lamivudine and Tenofovir Disoproxil Fumarate interfere with viral replication pathways through nucleoside and nucleotide reverse transcriptase inhibition. This triple antiviral combination is frequently selected in first-line HIV treatment protocols across institutional healthcare systems.

Genliva Wellness LLP specializes in antiretroviral pharmaceutical manufacturing in Gujarat supplying HIV treatment formulations for government procurement programs, international healthcare agencies, pharmaceutical distributors, and regulated export markets.

Dolutegravir + Lamivudine + Tenofovir Disoproxil Fumarate Tablets are formulated for combination antiretroviral therapy.

Triple antiviral HIV treatment formulation
Integrase inhibitor and reverse transcriptase inhibitor combination
Frequently utilized in first-line HIV treatment regimens
Optimized oral antiviral administration profile
Manufactured using premium pharmaceutical ingredients
Intended for long-term antiviral therapy programs

This formulation is prescribed in HIV infection management and antiviral treatment protocols.

Treatment of HIV infection
Management of combination antiretroviral therapy
Administered in viral suppression treatment programs
Utilized in long-term HIV care regimens
Targets HIV replication and viral integration pathways
Frequently selected in institutional antiviral therapies

Dolutegravir + Lamivudine + Tenofovir Disoproxil Fumarate Tablets deliver comprehensive antiviral therapy for HIV management.

Valuable in first-line HIV treatment protocols
Multi-mechanism antiviral activity against HIV
Frequently preferred in long-term antiretroviral care
Convenient oral antiviral treatment option
Useful in institutional HIV management programs
Maintains strong antiviral suppression performance

Dolutegravir & Lamivudine & Tenofovir Disoproxil Fumarate Tablet

Dolutegravir & Lamivudine & Tenofovir Disoproxil Fumarate Tablet